CYPC基因检测对药物的个体化治疗--培训课件.pptVIP

October, 2006 Hulot et al identify CYP2C19 polymorphisms as major determinant of variability in platelet aggregation in healthy subjects; additional publications later confirm this finding 2006 2007 2008 May, 2008 Trenk et al find CYP2C19 polymorphism is associated with adverse outcomes for patients on clopidogrel followed for one year 2009 December, 2008 Three additional outcome studies, including TRITON-TIMI 38, demonstrate a higher risk of CV events for CYP2C19 poor metabolizers on clopidogrel May, 2009 FDA revises clopidogrel label to include descriptive Information about individuals with